Removal of clinically relevant SARS-CoV-2 variants by an affinity resin containing Galanthus nivalis agglutininGalanthus nivalis agglutinin을 함유한 친화성 수지에 의한 임상적으로 관련된 SARS-CoV-2 변이체 제거Article Published on 2022-07-282022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 변종, [키워드] Adult patients affecting bind binding characterized clinically Concentration control sample COVID-19 COVID-19 infection decrease Efficacy Efficiency exceeded extrapolation Galanthus in viral indicated infectiousness lectin limitation mannose medium monoclonal antibodies Mutation mutations pandemic Patient removal resistance SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2 virus Seven Severe COVID-19 Infection severe disease Spike protein Structure the SARS-CoV-2 virus the spike protein therapy Treatment vaccination Vaccine variant variants viral envelope Viral load viral loads viral titer virulence [DOI] 10.1371/journal.pone.0272377 PMC 바로가기 [Article Type] Article
Deactylation by SIRT1 enables liquid–liquid phase separation of IRF3/IRF7 in innate antiviral immunity Research Published on 2022-07-252022-10-05 Journal: Nature Immunology [Category] 변종, [키워드] Activation affecting agonist antagonized antiviral immunity Critical deficiency demonstrated deteriorate DNA domain driver expression genetic code identify IFN IFN signaling IFN-I information inhibited Innate innate antiviral immunity Innate immunity interferon IRF3 IRF7 mechanism mice Mortality nucleus occur regulate rescued restored resulting SIRT1 Type I IFN Viral load viral replication [DOI] 10.1038/s41590-022-01269-0 [Article Type] Research
Intra-Familial Transmission Patterns of COVID-19 Infection among the Rural Residents of Ahmedabad, Gujarat, during an Epidemic of SARS-CoV-2 in IndiaArticle Published on 2022-07-222023-07-07 Journal: Japanese journal of infectious diseases [Category] COVID19(2023년), [키워드] Cycle threshold value Intra-familial transmission RT-PCR SARS-CoV-2 Viral load [DOI] 10.7883/yoken.JJID.2021.267
Favipiravir and/or nitazoxanide: a randomized, double-blind, 2×2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)Favipiravir 및/또는 nitazoxanide: IMSS(FANTAZE)에서 치료를 받는 의료 종사자, 가족 구성원 및 환자를 대상으로 한 COVID-19 조기 치료에 대한 무작위, 이중 맹검, 2x2 설계, 위약 대조 시험Randomized Controlled Trial Published on 2022-07-222022-09-11 Journal: Trials [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] 1:1 2×2 design absence Admission antimicrobial Antimicrobials Antiviral effect antiviral therapy Antiviral treatment antivirals appear assigned Asymptomatic blinded to treatment combination therapy Comorbidities Comorbidity Controlled trial COVID-19 COVID-19 disease disease double-blind early disease early phase early treatment example Favipiravir followed by Gender Genetic genetic mutation Health high risk Hospitalization Hypothesis in some include individuals Infection Inflammatory Influenza intensive care investigator investigators later phase morbidity and mortality Mutation mutation rate nitazoxanide obesity older patient outcome pandemic participant patients treated pharmacokinetics phase phase IIa Placebo placebo-controlled placebo-controlled clinical trial placebo-controlled trial positive presence or absence Prevent Primary outcome progression protocol randomised randomised controlled trial Randomized receive replicates SARS-CoV-2 secondary Secondary outcomes security Sepsis severe disease smoking status Social Security Stratification symptomatic symptomatic COVID-19 Symptoms tested the disease therapy those with comorbidity Toxicity treatment allocation Trial upper respiratory tract Viral load virus [DOI] 10.1186/s13063-022-06533-0 PMC 바로가기 [Article Type] Randomized Controlled Trial
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infectionSARS-CoV-2 감염 진단을 위한 신속한 현장 진료 항원 검사Review Published on 2022-07-222022-09-11 Journal: The Cochrane database of systematic reviews [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료제, [키워드] 95% CI 95% confidence interval absence access Accuracy age Antigen antigen test antigen tests approach assays Asymptomatic average Bern bioRxiv brand can not carried Chain Reaction Characteristics checked CIs Cohort Compliance conducted COVID-19 COVID-19 pandemic COVID-19 testing criteria criterion Data collection database demonstrated described detect diagnosis of SARS-CoV-2 diagnostic Diagnostic accuracy diagnostic tests Effectiveness eligible epidemiological estimate Europe evaluate evaluated Evidence exposure to False positive False positives global health groups Health Organization healthcare help heterogeneity highest include independent indication Infection Interpretation investigated logistic regression models management Mass screening measure medRxiv molecular test National Open Access Other participant Participants Patient care point-of-care polymerase chain polymerase chain reaction population groups Positive predictive value positive result PPV Predictive value presence or absence Prevalence produced public health QUADAS-2 random-effect ranged Rapid rapid antigen test Rapid antigen tests Rapid diagnostic test reduce reducing reference reference standard Reference standards repeated reported Research respiratory respiratory sample resulting reverse transcription reverse transcription polymerase chain reaction RT-PCR RT-PCR testing SARS-CoV-2 SARS-COV-2 infection Schools screened screening procedure screening programmes searched second Selection sensitivities sensitivity Sensitivity and specificity Seven Signs and symptoms Source Specificities specificity study cohort Study design Symptom symptom onset symptom status symptomatic symptomatic and asymptomatic symptomatic participant symptomatic participants symptomatic people symptoms of COVID-19 test negative test result Testing to define Transmission Triage unique University of Bern variable Viral Viral load viral loads website were used WHO World Health Organization [DOI] 10.1002/14651858.CD013705.pub3 PMC 바로가기 [Article Type] Review
The importance of effect sizes when comparing cycle threshold values of SARS-CoV-2 variantsSARS-CoV-2 변이체의 주기 임계값을 비교할 때 효과 크기의 중요성Article Published on 2022-07-212022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 치료기술, [키워드] age Alpha variant Alpha VOC Analysis ANOVA Beta calculation carried clinical setting Combination Ct values cycle threshold Cycle threshold value effect size effect sizes estimate Gender group investigated magnitude marker mechanism mutations Occurrence onset of symptoms outpatients P-value p-values Patient positive sample post-hoc Retrospective study SARS-CoV-2 SARS-CoV-2 variant significant effect significantly statistical analysis study period Transmission variants of SARS-CoV-2 Viral load viral variant VoC were recorded wild type [DOI] 10.1371/journal.pone.0271808 PMC 바로가기 [Article Type] Article
Nasal-spraying Bacillus spores as an effective symptomatic treatment for children with acute respiratory syncytial virus infectionRandomized Controlled Trial Published on 2022-07-202022-10-06 Journal: Scientific Reports [Category] 진단, [키워드] Bacillus children clinical study demonstrated effective Efficacy faster Impact Infection Inflammation nasopharyngeal sample pro-inflammatory cytokine Randomized reducing respiratory respiratory syncytial virus RSV spore Symptom Symptomatic treatment Symptoms tract Treatment Vaccine viral infection Viral load virus was reduced [DOI] 10.1038/s41598-022-16136-z PMC 바로가기 [Article Type] Randomized Controlled Trial
Development of a Rapid Live SARS-CoV-2 Neutralization Assay Based on a qPCR ReadoutqPCR 판독을 기반으로 한 Rapid Live SARS-CoV-2 중화 분석의 개발Article Published on 2022-07-202022-09-11 Journal: Journal of Clinical Microbiology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] antibody Antibody-mediated immunity antiviral activity calculate can be used characteristic controls correlation COVID-19 COVID-19 pandemic cross-neutralization demonstrated detect determine determined by development domain ELISA experiments faster generate gold gold standard Immunity Live virus natural infection neutralization Neutralization assay neutralization assays Neutralizing Neutralizing antibodies neutralizing antibody patient sera priority qPCR qRT-PCR Rapid Receptor-binding domain reduce reduction SARS-CoV-2 SARS-CoV-2 neutralizing antibodies SARS-CoV-2 neutralizing antibody SARS-CoV-2 qRT-PCR Sensitivity and specificity sera significantly standard curve surrogate neutralization assay tested vaccination variants Vero E6 Vero E6 cell VERO E6 cells Viral Viral load Viral RNA virus virus isolate Virus neutralization [DOI] 10.1128/jcm.00376-22 PMC 바로가기 [Article Type] Article
Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric StudiesSARS-CoV-2 바이러스 제거 동역학 특성화를 통해 항바이러스 약리학적 연구 설계 개선Article Published on 2022-07-192022-09-11 Journal: Antimicrobial Agents and Chemotherapy [Category] COVID19(2023년), SARS, 임상, 치료기술, 치료제, [키워드] analyzed Antiviral antiviral drug antiviral drugs antiviral effects antiviral treatments assessment clearance clearance rate clinical trials conducted Consensus COVID-19 illness Effect estimate exponential decay model individuals Infection Kinetics methodology Metrics molnupiravir Nasopharyngeal swab Nasopharyngeal swab samples Nirmatrelvir Patient Pharmacodynamics Phase 2 profile provide qPCR randomized trial randomized trials reduced reported robust Sample size sample sizes SARS-CoV-2 splines Statistical power time to clearance. Trial viral clearance Viral load virological response [DOI] 10.1128/aac.00192-22 PMC 바로가기 [Article Type] Article
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection단일 클론 항체 치료는 SARS-CoV-2 감염에서 빠른 배양 전환을 유도합니다Clinical Trial Published on 2022-07-192022-09-11 Journal: Cell Reports Medicine [Category] COVID19(2023년), SARS, 임상, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus antibody treatment bamlanivimab benefit clearance collected coronavirus Coronavirus 2019 COVID COVID therapies COVID-19 Culture mAb mAbs monoclonal monoclonal antibodies monoclonal antibody nasal swab offer onward transmission participant performed Placebo qPCR raise receiving recrudescence reducing resistance respiratory SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 subset Transmission Treatment Trial Viral viral culture Viral load Viral RNA virus while [DOI] 10.1016/j.xcrm.2022.100678 PMC 바로가기 [Article Type] Clinical Trial